Ralph Weichselbaum to Herpesvirus 1, Human
This is a "connection" page, showing publications Ralph Weichselbaum has written about Herpesvirus 1, Human.
Connection Strength
2.251
-
Increased oncolytic efficacy for high-grade gliomas by optimal integration of ionizing radiation into the replicative cycle of HSV-1. Gene Ther. 2011 Nov; 18(11):1098-102.
Score: 0.289
-
Tumor genotype determines susceptibility to oncolytic herpes simplex virus mutants: strategies for clinical application. Future Oncol. 2007 Oct; 3(5):545-56.
Score: 0.225
-
Systemic delivery of (gamma1)34.5-deleted herpes simplex virus-1 selectively targets and treats distant human xenograft tumors that express high MEK activity. Cancer Res. 2007 Sep 01; 67(17):8301-6.
Score: 0.224
-
Activated MEK suppresses activation of PKR and enables efficient replication and in vivo oncolysis by Deltagamma(1)34.5 mutants of herpes simplex virus 1. J Virol. 2006 Feb; 80(3):1110-20.
Score: 0.201
-
Ionizing radiation activates late herpes simplex virus 1 promoters via the p38 pathway in tumors treated with oncolytic viruses. Cancer Res. 2005 Oct 15; 65(20):9479-84.
Score: 0.197
-
The use of a genetically engineered herpes simplex virus (R7020) with ionizing radiation for experimental hepatoma. Gene Ther. 2002 Jan; 9(1):75-80.
Score: 0.151
-
Molecular targeting of gene therapy and radiotherapy. Acta Oncol. 2001; 40(6):735-8.
Score: 0.141
-
Accumulation of specific RNAs encoding transcriptional factors and stress response proteins against a background of severe depletion of cellular RNAs in cells infected with herpes simplex virus 1. Proc Natl Acad Sci U S A. 1999 Oct 12; 96(21):12062-7.
Score: 0.130
-
Ionizing radiation improves survival in mice bearing intracranial high-grade gliomas injected with genetically modified herpes simplex virus. Clin Cancer Res. 1999 Jun; 5(6):1517-22.
Score: 0.127
-
Evidence for the Use of Multiple Mechanisms by Herpes Simplex Virus-1 R7020 to Inhibit Intimal Hyperplasia. PLoS One. 2015; 10(7):e0130264.
Score: 0.096
-
A phase 1 trial of oncolytic HSV-1, G207, given in combination with radiation for recurrent GBM demonstrates safety and radiographic responses. Mol Ther. 2014 May; 22(5):1048-55.
Score: 0.088
-
Attenuated herpes simplex virus 1 blocks arterial apoptosis and intimal hyperplasia induced by balloon angioplasty and reduced blood flow. Proc Natl Acad Sci U S A. 2007 Jul 24; 104(30):12474-8.
Score: 0.056
-
ReVOLT: radiation-enhanced viral oncolytic therapy. Int J Radiat Oncol Biol Phys. 2006 Nov 01; 66(3):637-46.
Score: 0.053
-
Modulation of vascular remodeling induced by a brief intraluminal exposure to the recombinant R7020 strain of Herpes simplex-1. J Vasc Surg. 2005 Jan; 41(1):115-21.
Score: 0.047
-
Oct-1 is posttranslationally modified and exhibits reduced capacity to bind cognate sites at late times after infection with herpes simplex virus 1. J Virol. 2003 Nov; 77(22):11927-32.
Score: 0.043
-
Herpes simplex virus 1 activates cdc2 to recruit topoisomerase II alpha for post-DNA synthesis expression of late genes. Proc Natl Acad Sci U S A. 2003 Apr 15; 100(8):4825-30.
Score: 0.041
-
Prevention of restenosis by a herpes simplex virus mutant capable of controlled long-term expression in vascular tissue in vivo. Gene Ther. 2001 Dec; 8(24):1840-6.
Score: 0.038
-
Posttranslational processing of infected cell proteins 0 and 4 of herpes simplex virus 1 is sequential and reflects the subcellular compartment in which the proteins localize. J Virol. 2001 Sep; 75(17):7904-12.
Score: 0.037
-
E2F proteins are posttranslationally modified concomitantly with a reduction in nuclear binding activity in cells infected with herpes simplex virus 1. J Virol. 2000 Sep; 74(17):7842-50.
Score: 0.035
-
The disappearance of cyclins A and B and the increase in activity of the G(2)/M-phase cellular kinase cdc2 in herpes simplex virus 1-infected cells require expression of the alpha22/U(S)1.5 and U(L)13 viral genes. J Virol. 2000 Jan; 74(1):8-15.
Score: 0.033